Can Europe Afford Innovation?
(2008; 3 pages)

Abstract

Finding a balance between reward for innovation, improved patient access to innovative medicines and controlling budgets remains a challenge for decision-makers, patients and industry in Europe. The industry has a clear preference for market-based pricing, yet, the predominance of administered pricing in most European countries, given, alternatives need to be explored. Today, Europe sees health care innovation too much as a cost rather than an asset. There is a need for constructive dialogue on what constitutes the value of new medicines and how added therapeutic value should be rewarded.

 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: August 29, 2014